Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1899 1
1902 1
1942 1
1945 1
1948 1
1951 1
1954 1
1955 1
1960 1
1965 1
1970 3
1971 4
1972 4
1973 5
1974 1
1976 3
1977 3
1978 5
1979 2
1980 5
1981 4
1982 4
1983 8
1984 10
1985 9
1986 15
1987 9
1988 4
1989 6
1990 10
1991 8
1992 8
1993 14
1994 7
1995 10
1996 11
1997 9
1998 9
1999 10
2000 15
2001 16
2002 20
2003 20
2004 33
2005 22
2006 29
2007 21
2008 29
2009 43
2010 40
2011 36
2012 44
2013 54
2014 42
2015 46
2016 52
2017 51
2018 58
2019 64
2020 66
2021 84
2022 74
2023 9
Text availability
Article attribute
Article type
Publication date

Search Results

1,045 results
Results by year
Filters applied: . Clear all
Page 1
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. Sehn LH, et al. Among authors: herrera af. J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6. J Clin Oncol. 2020. PMID: 31693429 Free PMC article. Clinical Trial.
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Locke FL, et al. Among authors: herrera af. Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2. Lancet Oncol. 2019. PMID: 30518502 Free PMC article. Clinical Trial.
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi PN, Beitinjaneh A, Reagan PM, Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M. Shadman M, et al. Among authors: herrera af. Blood. 2022 Mar 3;139(9):1330-1339. doi: 10.1182/blood.2021013289. Blood. 2022. PMID: 34570879 Free PMC article.
[Adolescents and smoking].
Herrera AM, Corvalán MP. Herrera AM, et al. Rev Chil Pediatr. 2017 Dec;88(6):697-698. doi: 10.4067/S0370-41062017000600697. Rev Chil Pediatr. 2017. PMID: 29546916 Free article. Spanish. No abstract available.
Microglia: Agents of the CNS Pro-Inflammatory Response.
Rodríguez-Gómez JA, Kavanagh E, Engskog-Vlachos P, Engskog MKR, Herrera AJ, Espinosa-Oliva AM, Joseph B, Hajji N, Venero JL, Burguillos MA. Rodríguez-Gómez JA, et al. Among authors: herrera aj. Cells. 2020 Jul 17;9(7):1717. doi: 10.3390/cells9071717. Cells. 2020. PMID: 32709045 Free PMC article. Review.
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF. Advani RH, et al. Among authors: herrera af. Blood. 2021 Aug 12;138(6):427-438. doi: 10.1182/blood.2020009178. Blood. 2021. PMID: 33827139 Free article. Clinical Trial.
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.
Sehn LH, Hertzberg M, Opat S, Herrera AF, Assouline S, Flowers CR, Kim TM, McMillan A, Ozcan M, Safar V, Salles G, Ku G, Hirata J, Chang YM, Musick L, Matasar MJ. Sehn LH, et al. Among authors: herrera af. Blood Adv. 2022 Jan 25;6(2):533-543. doi: 10.1182/bloodadvances.2021005794. Blood Adv. 2022. PMID: 34749395 Free PMC article. Clinical Trial.
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, Metzger M, Morgan D, Mulroney C, Pullarkat ST, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Torka P, Winter JN, Yahalom J, Yang JC, Burns JL, Campbell M, Sundar H. Hoppe RT, et al. Among authors: herrera af. J Natl Compr Canc Netw. 2022 Apr;20(4):322-334. doi: 10.6004/jnccn.2022.0021. J Natl Compr Canc Netw. 2022. PMID: 35390768
1,045 results